Screener
Immunovant, Inc. IMVT Interest Expense
Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Acquired in-process research and development | — | — | 12,500 |
| General and administrative | 76,242 | 77,235 | 57,281 |
| Total operating expenses | 532,902 | 438,152 | 282,709 |
| Interest income, net | (25,330) | (24,732) | (24,948) |
| Other (income) expense, net | (2,181) | (471) | 1,008 |
| Loss before provision for income taxes | (505,391) | (412,949) | (258,769) |
| Provision for income taxes | 215 | 891 | 567 |
| Net loss | $(505,606) | $(413,840) | $(259,336) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s interest expense?
- Immunovant, Inc. (IMVT) reported interest expense of $8.06M in Q1 2026.
- How has Immunovant, Inc.'s interest expense changed year-over-year?
- Immunovant, Inc.'s interest expense increased by 17.0% year-over-year, from $6.89M to $8.06M.
- What is the long-term trend for Immunovant, Inc.'s interest expense?
- Over 3 years (2023 to 2026), Immunovant, Inc.'s interest expense has grown at a 49.5% compound annual growth rate (CAGR), from $7.58M to $25.33M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Immunovant, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude